pregabalin has been researched along with Somatoform-Disorders* in 4 studies
2 review(s) available for pregabalin and Somatoform-Disorders
Article | Year |
---|---|
A case report of pregabalin use disorder with co-morbid somatic symptom disorder and depression.
Topics: Adult; Analgesics; Anti-Anxiety Agents; Chronic Pain; Depressive Disorder; Humans; Male; Pregabalin; Somatoform Disorders; Substance-Related Disorders | 2018 |
[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].
The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF; registration number 041/004) was planned starting in March 2011.. The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy ("Deutsche Interdisziplinären Vereinigung für Schmerztherapie", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. The recommendations were based on level of evidence, efficacy (meta-analysis of the outcomes pain, sleep, fatigue and health-related quality of life), acceptability (total dropout rate), risks (adverse events) and applicability of treatment modalities in the German health care system. The formulation and grading of recommendations was accomplished using a multi-step, formal consensus process. The guidelines were reviewed by the boards of the participating scientific medical societies.. Amitriptyline and-in case of comorbid depressive disorder or generalized anxiety disorder-duloxetine are recommended. Off-label use of duloxetine and pregabalin can be considered in case of no comorbid mental disorder. Strong opioids are not recommended. The English full-text version of this article is available at SpringerLink (under "Supplemental"). Topics: Amitriptyline; Analgesics; Analgesics, Opioid; Antidepressive Agents; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Cooperative Behavior; Depressive Disorder, Major; Duloxetine Hydrochloride; Fibromyalgia; gamma-Aminobutyric Acid; Germany; Humans; Interdisciplinary Communication; Off-Label Use; Patient Care Team; Pregabalin; Somatoform Disorders; Thiophenes | 2012 |
2 other study(ies) available for pregabalin and Somatoform-Disorders
Article | Year |
---|---|
Pregabalin in patients with antidepressant treatment-resistant somatoform disorders: a case series.
Topics: Adult; Analgesics; Antidepressive Agents; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pain; Pain Measurement; Pregabalin; Somatoform Disorders; Treatment Outcome | 2007 |
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
Anticonvulsants that act as ligands at alpha(2)delta subunits of voltage-gated calcium channels are proving to be novel treatments for chronic pain. Topics: Acetates; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Ligands; Pain; Pain Measurement; Pregabalin; Somatoform Disorders; Synaptic Transmission | 2004 |